Effect of pravastatin on endothelial dysfunction in children with medium to giant coronary aneurysms due to Kawasaki disease

World Journal of Pediatrics

Volumn 10, Issue 3, 2014, Pages 232-237

  Duan, Chao ^a   Du, Zhong Dong ^a   Wang, Yu ^a   Jia, Li Qun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

coronary aneurysm; endothelial function; endothelial progenitor cells; Kawasaki disease; statins

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE KINASE; DIPYRIDAMOLE; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DILATATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; THORAX PAIN; VOMITING; BLOOD; CASE CONTROL STUDY; COMPLICATION; CORONARY ANEURYSM; DRUG EFFECTS; ECHOGRAPHY; FOLLOW UP; METABOLISM; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CORONARY ANEURYSM; ENDOTHELIUM, VASCULAR; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRAVASTATIN; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84920693867     PISSN: 17088569     EISSN: 18670687     Source Type: Journal    
DOI: 10.1007/s12519-014-0498-5     Document Type: Article

References (30)

1. Du ZD, Zhao D, Du J, Zhang YL, Lin Y, Liu C, et al. Epidemiologic study on Kawasaki disease in Beijing from 2000 through 2004. Pediatr Infect Dis J 2007;26:449–451.
2. Duan C, Du ZD. Analysis of 63 cases of Kawasaki disease complicated with coronary aneurysms. Chin J Practical Pediatr 2009;24:37–40.
3. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379–1385.
4. Fulton DR, Newburger JW. Long-term cardiac sequelae of Kawasaki disease. Curr Rheumatol Rep 2000;2:324–329.
5. Ikemoto Y, Ogino H, Teraguchi M, Kobayashi Y. Evaluation of preclinical atherosclerosis by flow-mediated dilatation of the brachial artery and carotid artery analysis in patients with a history of Kawasaki disease. Pediatr Cardiol 2005;26:782–786.
6. Kadono T, Sugiyama H, Hoshiai M, Osada M, Tan T, Naitoh A, et al. Endothelial function evaluated by flow-mediated dilatation in pediatric vascular disease. Pediatr Cardiol 2005;26:385–390.
7. Niboshi A, Hamaoka K, Sakata K, Yamaguchi N. Endothelial dysfunction in adult patients with a history of Kawasaki disease. Eur J Pediatr 2008;167:189–196.
8. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349–1357.
9. Sasaki S, Nakagawa M, Nakata T, Azuma A, Sawasa S, Takeda K, et al. Effects of pravastatin on exercise electrocardiography test performance and cardiovascular mortality and morbidity in patients with hypercholesterolemia: Lipid Intervention Study in Kyoto. Circ J 2002;66:47–52.
10. Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 2002;66:1096–1100.
11. Davidson MH. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation 2005;111:2280–2281.
12. Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: knowledge base, limitations, and future directions. Pediatrics 2007;119:370–380.
13. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528–5240.
14. Lusis AJ. Atherosclerosis. Nature 2000;407:233–241.
15. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708–1733.
16. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257–265.
17. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999;340:115–126.
18. Huang SM, Weng KP, Chang JS, Lee WY, Huang SH, Hsieh KS. Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease: a pilot study. Circ J 2008;72:1583–1587
19. Ikemoto Y, Ogino H, Teraguchi M, Kobayashi Y. Evaluation of preclinical atherosclerosis by flow-mediated dilatation of the brachial artery and carotid artery analysis in patients with a history of Kawasaki disease. Ped Cardiol 2005;26:782–786.
20. Kadono T, Sugiyama H, Hoshiai M, Osada M, Tan T, Naitoh A. Endothelial function evaluated by flow-mediated dilatation in pediatric vascular disease. Ped Cardiol 2005;26:385–390.
21. Niboshi A, Hamaoka K, Sakata K, Yamaguchi N. Endothelial dysfunction in adult patients with a history of Kawasaki disease. Eur J Pediatr 2008;167:189–196.
22. McCrindle BW, McIntyre S, Kim C, Lin T, Adeli K. Are patients after Kawasaki disease at increased risk for accelerated atherosclerosis? J Pediatr 2007;151:244–248, 248.e1.
23. Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, et al. A HMG-CoA reductase inhibitor possesses a potent antiatherosclerotic effect other than serum lipid lowering effects—the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 2001;155:347–357.
24. Sasaki J, Arakawa K, Iwashita M, Matsushita Y, Kono S; Kyushu Lipid Intervention Study (KLIS) Group. Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men: the Kyushu Lipid Intervention Study. Circ J 2003;67:473–478.
25. Newburger JW, Burns JC, Beiser AS, Loscalzo J. Altered lipid profile after Kawasaki syndrome. Circulation 1991;84:625–631.
26. Niboshi A, Hamaoka K, Sakata K, Yamaguchi N. Endothelial dysfunction in adult patients with a history of Kawasaki disease. Eur J Pediatr 2008;167:189–196.
27. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026–2033.
28. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. Circulation 1996;94:273–278.
29. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135–1143.
30. Mitani Y, Sawada H, Hayakawa H, Aoki K, Ohashi H, Matsumura M, et al. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: association between inflammation and late coronary sequelae in Kawasaki disease. Circulation 2005;111:38–43.